FDA eyes global bans on Spirochlorphine and weird drug cousins
Published Date: 8/26/2026
Notice
Summary
The FDA is asking the public to share their thoughts on eight drugs that might get new international rules to control their use and abuse. This affects doctors, patients, and drug makers because it could change how these drugs are used medically or restricted worldwide. Comments are open until September 3, 2026, so jump in and have your say before the deadline!
Analyzed Economic Effects
5 provisions identified: 2 benefits, 3 costs, 0 mixed.
International Controls Could Limit Trade
The notice says that if the Expert Committee recommends international controls, such controls could limit the manufacture and distribution (including import/export) of the listed substances and could impose certain recordkeeping requirements. The FDA is seeking public comment through September 3, 2026.
Etomidate Pre-Review Could Affect Access
Etomidate is approved in the United States for induction of general or supplemental anesthesia, but the ECDD will perform a pre-review to decide whether a full critical review is justified. Other countries adopted controls (e.g., UK: July 2025; South Korea: February 2025; Taiwan: November 2024; Hong Kong: February 2025).
Medetomidine Review and Veterinary Risks
Medetomidine is approved for veterinary use only and has been increasingly detected as an adulterant in illicit drug supplies; Pennsylvania classified it as Schedule III in 2026. The ECDD will pre-review medetomidine to assess whether to advance to a full critical review.
Federal Temporary Schedule I Actions Announced
The notice states that etomethazene is temporarily controlled in Schedule I under the Controlled Substances Act as of October 15, 2025, and that the DEA published a notice of intent on July 1, 2026 to temporarily control cychlorphine and spirochlorphine in Schedule I. Cychlorphine has been confirmed in 225 law enforcement seizures and associated with at least 55 fatalities in the United States as of early 2026.
Benzodiazepines Under Critical Review
The ECDD will conduct critical reviews of three designer benzodiazepines — clobromazolam (phenazolam), desalkylgidazepam (bromonordiazepam), and ethylbromazolam — which are not currently controlled under the CSA and have no approved U.S. medical uses. Desalkylgidazepam has been detected in 227 polydrug intoxication and fatality cases; ethylbromazolam was detected in 13 toxicology cases and 93 drug material cases by October 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-17379, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Application for Designation as National Recreation Trail or National Water Trail
In accordance with the Paperwork Reduction Act of 1995, we, the National Park Service (NPS, we) are proposing to reinstate a previously approved collection without change.
Next: 2026-17382, Performance Review Board, Senior Executive Service (SES)
The Civil Service Reform Act of 1978, Public Law 95-454 (Section 405) requires that appointments of individual members to the Performance Review Board (PRB) be published in the Federal Register.